France's Boiron Strikes Deal With Bionorica As Q3 Sales Edge Up
Boiron has gained the rights to distribute Bionorica's Canephron herbal medicine in France as it continues to diversify its portfolio away from homeopathy.
You may also be interested in...
France's Boiron Reaping The Benefits Of Product Investments
Boiron's decision to diversify its portfolio away from non-proprietary homeopathic medicines is paying off, with sales for the opening nine months of 2022 up by a quarter, driven by new product launches in categories such as cosmetics and dietary supplements.
EU Business Round-Up: BioGaia Creates Investment Arm, Boiron Grows In Spain, GSK Ends Hikma Talks
Latest European consumer health business news: BioGaia sets up an investment arm to identify interesting start-ups, France's Boiron expands its Spain offering with Iprad deal, and GSK ends talks with Hikma over the sale of its Egyptian OTC business.
France's Boiron Diversifies Into Probiotics To Arrest Sales Decline
Homeopathy specialist Boiron its diversifying its offering into the increasingly popular probiotics segment with launches underway in France, Italy and Spain, as well as Eastern Europe.